Copenhagen-based company Magcath is all set for the European launch of its female incontinence treatment device- Obtinu, having secured an additional €535,000 from its existing angel investors. Magcath is a medical device company, and had already secured an investment of €737,000 in July 2024 from the same group of Danish and Swiss investors. After the initial launch in Denmark, Magcath is looking to expand into other European markets.
“There is no product on the market that is identical to Obtinu. Obtinu’s magnetic opening and closing valve, which makes it possible to wear it all day and still urinate as needed, is unique,” said Camilla Harder Hartvig, recently appointed chairperson of Magcath, in a statement to MedWatch.
Obtinu is a silicone urethral device with a magnetic valve for controlling urination, and allows women to wear it throughout the day without requiring replacement. The company expects to receive a CE mark approval for this product by July 2025. It addresses a concern that affects approximately 128 million women globally, and is experienced by 25-45% women at some point in their lives.
Magcath was founded in 2013, and has secured approximately €2.8 million in total funding from investors including Seed Capital, Innovation Fund Denmark, and the Market Development Fund. While the company’s original launch was targeted to be in 2018, it was delayed due to improvements in user-friendliness and the transition from MDD to MDR regulations in Europe.
